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ABSTRACT
This review summarizes the epidemiology, clinical course, and diagnosis of malaria. The influence
of infection during pregnancy upon maternal and neonatal anemia, stillbirth, preterm labor, low
birth weight, and congenital malaria is discussed. Options for treatment and prophylaxis during
pregnancy are presented. Infect. Dis. Obstet. Gynecol. 5:45-51, 1997. (C) 1997 Wiley-Liss, Inc.
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hile malaria is generally considered a dis-
ease of the third world, 1,419 cases were re-
ported in the United States last year. Because the
disease is rare, practitioners may be unaware of the
presentation. Malaria is a potentially fatal illness if
not diagnosed and treated in a timely fashion.
PATHOGENESIS
Malaria is caused by the genus Plasmodium. There
are four species which infect man: P. falciparum, P.
vivax, P. ovale, and P. malariae, z The infection is
transmitted through the Anopheles mosquito. The
life cycle is complex with both sexual and asexual
reproduction (Fig. 1). The mosquito injects plas-
modial sporozoites from its salivary glands into the
bloodstream of its victim. The sporozoites in turn
infect hepatocytes where they develop and multi-
ply in a process known as extra-erythrocytic schi-
zogony. Within 1-2 weeks, the hepatocytes rupture
releasing merozoites. These merozoites invade red
blood cells and begin erythrocyte schizogonym
maturation through the trophozoite stage to be-
come schizonts. Schizonts then develop into ma-
ture merozoites which are released from red blood
cells to repeat the cycle. Some of the merozoites
will develop into male and female gametocytes.
When the female Anopheles mosquito ingests the
gametocytes, sexual reproduction occurs within the
mosquito producing additional sporozoites, e P.
vivax and P. ovale have a dormant phase. Rather
than entering extra-erythrocytic schizogony, the
sporozoites become hypnozoites. In this form, they
do not cause symptoms, however, they may reacti-
vate at a later time causing clinical illness.
P. falciparum is the most widely distributed of
the malaria species. It is found throughout Mexico,
Haiti, and the Dominican Republic. It is also found
in the equatorial regions of South America, Africa,
and Asia. P. vivax is found in the Americas, Middle
East, and North Africa.
The species P. falciparum is of special concern
for three reasons. First, it is widely distributed.
Second, strains of P. falciparum continue to emerge
which are resistant to chloroquine. Finally, P. fal-
ciparurn causes the most serious complications be-
cause it results in higher levels of parasitemia.
3
EPIDEMIOLOGY
The incidence of malaria is increased during preg-
nancy.3 In holoendemic areas, the peak prevalence
of P. falciparum parasitemia occurs between 9 and
16 weeks’ gestation.4 Primigravidas in particular
*Correspondence to: Dr. Lisa M. Hollier, Department of Obstetrics and Gynecology, University of Texas Southwestern
Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-9032.
Received 10 October 1996
Obstetrical Case Report Accepted 9 May 1997MALARIA IN PREGNANCY HOLLIER ET AL.
The female Anopheles
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Fig. I. Plasmodium life cycle (adapted from Zucker and Campbell’).
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have increased susceptibility to malaria when com-
pared to multigravid women. This vulnerability oc-
curs even in areas where malaria is endemic.5
The reason for the increased susceptibility in
pregnancy has long been a topic of research. Pos-
tulated mechanisms include alterations in hor-
monal factors as well as changes in cell-mediated
and humoral antibody responses. Recently, several
investigators have found that a placental protein,
chondroitin sulfate A (CSA), may play a role.6,7 Ma-
laria-infected red blood cells produce surface pro-
teins that allow them to bind to particular tissues.
Fried and Duffys have isolated red blood cells in-
fected with P. falciparum from human placentas.
These cells bind only to CSA and not to other
known infected red blood cell receptors. These
cells also bind to uninfected placentas in the same
distribution as in naturally infected placentas. The
authors propose that a woman becomes highly sus-
ceptible to malarial infection during her initial
pregnancy when she first provides the placental
substrate CSA. This exposure selects CSA-binding
parasites for growth. With subsequent pregnancies,
the woman develops increasing immunity to the
selected subpopulation, reducing the frequency
and severity of infection.
COMPLICATIONS OF MALARIA
IN PREGNANCY
A wide variety of complications can arise from ma-
larial infection. Anemia is very common and occurs
even in endemic regions. Abortion and premature
delivery can occur in women without immunity.
Intrauterine growth restriction, congenital malaria,
and pcrinatal death are also risks.
Anemia
The prevalence of anemia is highest between 16
and 28 weeks’ gestation, following the peak preva-
lence of parasitemia.9’1 Non-immune women will
develop significant anemia with malarial infection.
The mechanism for the anemia is multifaceted.
Immune-mediated hemolysis occurs in the periph-
eral circulation. In addition, red cells coated with
immune complexes are cleared from the circulation
by the spleen. Sequestration of infected erythro-
cytes in the spleen, liver, bone marrow, and pla-
centa also decreases the hematocrit. The degree of
splenomcgaly has been correlated with the severity
of anemia in a study by Brabin et al.3
Nutritional deficiencies further compound the
anemia. Iron stores may be decreased by repeated
pregnancies as well as inadequate diet. Folate de-
ficiency with resulting megaloblasts occurs when
the diet is unable to supply the increased demands
of erythropoiesis.
Dyserythropoiesis is yet another potential con-
tributor to the anemia observed in infected pa-
tients. This abnormal bone marrow response to
anemia has been observed in children 11 and in-
cludes erythroblast multinuclearity, karyorrhexis,
incomplete and unequal amitotic nuclear division,
and cytoplasmic bridging.
In addition to maternal anemia, malaria is also
associated with fetal anemia. Brabin lz compared
maternal and cord hemoglobin values in malaria-
endemic and non-endemic regions. The range of
maternal values in the population of pregnant
women not exposed to malaria was 4.7-14.2 g/dl.
The lowest cord value in this series of reports was
12.6 g/dl for a severely iron-deficient group of
women (Hgb 4.7 g/dl). In contrast, in pregnant
populations from malaria-endemic regions, cord
hemoglobin values less than 13 were not uncom-
mon and values as low as 7.4 g/dl were found in
certain populations. Thus, it appears that exposure
to malaria produces a degree of fetal anemia which
seems greater than would be expected as a result of
maternal iron deficiency alone.
Stillbirth
Malaria is associated with an increased risk of still-
birth. While data to determine the precise mecha-
nism of fetal death are lacking, several risk factors
have been identified. Primigravidity is associated
with stillbirth rates in excess of 10% in rural Gam-
bia where malaria is endemic. For multigravidas,
rates range from 0.9 to 6.9% in malaria-endemic
areas. Other associated factors are hyperpyrexia,
14
severe anemia, placental parasitemia, and hypo-
glycemia. 14 When placental infection occurs early
in gestation, spontaneous abortion can result.
Preterm Labor
There is currently little data demonstrating a causal
relationship between malaria and preterm labor.
Studies from sub-Saharan Africa are often limited
by imprecise estimates of gestational age.
Low Birth Weight
The prevalence of low birth weight (<2,500 g) in-
fants in malaria-endemic areas ranges from 15 to
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30%. 17,18 Diverse factors are associated with the
delivery of these small infants including environ-
mental and demographic characteristics. Several
studies have demonstrated that the prevalence of
low birth weight infants is higher among primi-
gravidas than multigravidas. 17,19
Maternal complications of Plasmodium infection
such as anemia are also associated with low birth
weight. Both the multifactorial nature of the prob-
lem and difficulty in accurate assessment of gesta-
tional age make determination of the direct effect
of malaria on birth weight elusive.
Contributions to abnormal growth by circulating
malaria parasites, malaria-associated placental le-
sions, and maternal anemia were evaluated by
Meuris and colleagues. 17 The prevalence of low
birth weight was 15% in the total population; how-
ever, in women without these factors, only 6.4% of
infants had low birth weight. When both circulat-
ing parasites and placental lesions were found at
birth, the percentage of low birth weight was
25.9%, and rose to 29.2% when maternal anemia
(Hgb < 10) was also present.
One theoretical explanation for the association
between infection and fetal growth abnormalities is
placental damage. Malaria infection causes a thick-
ening of the trophoblastic basement mem-
brane,e-ee Placental sinusoids are closely packed
with parasitized red blood cells. This, together with
an excess of intervillous macrophages and perivil-
lous fibrin deposition, may be expected to cause
microcirculatory obstruction and a reduction in nu-
trients supplied to the fetus.
Congenital Malaria
Congenital malaria is defined as clinical malaria
with peripheral parasitemia within 2 weeks of
birth. It is important to note that this infection can
be acquired by the fetus during the pregnancy
(congenital) or during labor (perinatally).e3 The in-
cidence of congenital malaria in infants of immune
mothers in endemic areas is 0.3%, compared with
1-10% in infants of non-immune mothers in the
14 same area.
Symptoms include anorexia, irritability, nausea,
vomiting, and jaundice,z3 Splenomegaly and asso-
ciated thrombocytopenia are very common. The
characteristics of congenital malaria can be modi-
fied by maternal antibody status. Transplacental
passage of maternal immunoglobulin in the third
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trimester can potentially prevent or result in milder
or delayed disease in the neonate. The gradual dis-
appearance of the antibodies allows for the acqui-
sition of mosquito-transmitted disease by the in-
fant in endemic areas.
PRESENTATION AND DIAGNOSIS
Moore et al.24 reviewed 59 cases of malaria in
Texas that occurred from 1990 to 1993. Six of the
patients in this series were pregnant. Fever was a
universal finding and chills occurred in 96%. Head-
ache was present in 86%. Other associated symp-
toms included nausea, vomiting, abdominal pain,
diarrhea, and cough. Physical examination revealed
splenomegaly in 40%. Laboratory abnormalities in-
cluded elevated lactate dehydrogenase (>200 U/l),
elevated bilirubin (>1.0 mg/dl), thrombocytopenia
(<150 109 1), elevated creatinine (>1 mg/dl), and
anemia (Hct < 33 vol%).
Cerebral dysfunction is the most common se-
vere manifestation of (P. falciparum) malaria in
man. Symptoms can be gradual in onset or coma
can follow a generalized convulsion. Other symp-
toms include delirium and focal "fits" without loss
of consciousness,es Several hypotheses have been
put forth to explain the disease process including
sludging or obstruction of the cerebral vessels, as
well as a breakdown of the vascular endothelium
leading to cerebral edema.
Other complications of severe malaria infection
include renal failure, adult respiratory distress syn-
drome, and intravascular hemolysis. P. falciparum is
usually the etiologic agent; other species rarely
cause severe disease.
Fever and chills occur at the time of rupture of
erythrocytes containing merozoites,z6 Cytokines,
e.g., tumor necrosis factor-alpha (TNF-ot) and in-
terleukin-1, are both thought to play a role in the
systemic manifestations of the illness. Cytoadher-
ence also plays a role in the establishment of severe
disease.
Both acute infection with malaria and its therapy
are associated with hypoglycemia, ls’16 Pregnancy is
associated with an increased sensitivity of the pan-
creatic 13 cells to stimulants for insulin release.
Therefore, pregnant patients are particularly sus-
ceptible to hyperinsulinemia caused by quinine
and quinidine.
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Diagnosis
A fresh sample of blood should be obtained for
both thin and thick smear preparations. For thin
smears, Wright stains alone are not satisfactory; the
addition of 3% Giemsa or Giemsa alone improves
the parasite yield. In inexperienced hands, the thin
smear may be easier to read. The thick smear, how-
ever, provides the experienced technician higher
sensitivity due to higher concentration of the para-
sites. Several smears may be necessary to establish
the diagnosis in women with low parasite density,e
TREATMENT
There are three basic principles which guide
therapy: the infecting species, parasite density, and
clinical status of the patient, z Early identification of
the species is important because the illness caused
by P. falciparum can progress rapidly. Pregnant
women are at especially high risk; therefore, early
and aggressive therapy is critical. In addition to
giving a drug which rapidly kills the parasites, sup-
portive therapy is very important. Fluid status and
serum glucose need to be monitored. Daily blood
smears should be obtained until negative.
Infections caused by P. vivax, P. ovale, and P.
malariae should be treated with chloroquine. P.
vivax and P. ovale both have dormant forms, re-
ferred to as hypnozoites, which are asymptomatic.
These forms are not susceptible to chloroquine
and, therefore, in non-pregnant individuals a
course of primaquine is added at the completion of
the initial therapy. Prior to treatment with prima-
quine, individuals at risk for glucose-6-phosphate
deficiency should be evaluated. Those patients
with <10% residual enzyme activity should not be
treated due to the risk of hemolytic disease.
Primaquine can cause hemolytic disease in the
fetus, so it is not recommended in pregnancy.
Rather, the gravida should be maintained on pro-
phylactic doses of chloroquine until delivery in an
effort to prevent relapse during gestation. She can
then be treated with primaquine in the postpartum
period, e
When infection is caused by P. falciparum, it is
important to know if the infection was acquired in
an area with reported chloroquine resistance. If the
infection was acquired in an area without reported
resistance, treatment with oral chloroquine is ad-
equate. For infections thought to be caused by re-
TABLE I. Treatment options safe for use during
pregnancy
Drug Dosage
CQ sensitive
Chloroquine
CQ resistant
Quinine sulfate
with clindamycin
Mefloquine
Intravenous
Quinidine gluconate
10 mg base/kg p.o. followed by 10 mg
base/kg p.o. at 24 h and 5 mg base/kg
p.o. at 48 h
650 mg salt p.o. q 8 h x 3-7 days
450 mg p.o. q 8 h x 3 days
15 mg base/kg in a single dose
10 mg/kg loading dose over I-2 h
0.02 mg/kg/min continuous maintenance
infusion
aCQ chloroquine prophylaxis.
bAntimalarial drug doses can be expressed in terms of either the base
or the salt of the drug. Because dosages differ for the different forms,
clinicians must specify the form desired.
sistant organisms, quinine and clindamycin can be
used. Mefloquine is another alternative that can be
used in pregnancy (Table 1). Little information is
currently available on the use of artemisinin deriva-
tives in pregnancy, however, their use is recom-
mended for the treatment of mefloquine-resistant,
P. falciparum infections after the first trimester,e7
Indications for intravenous therapy include in-
ability to tolerate oral therapy and parasite density
exceeding 5%. e Intravenous quinidine is given to
maintain levels of 3-7 mg/1 (Table 1). These pa-
tients require central venous pressure monitoring
as well as continuous cardiac monitoring for early
detection of prolongation of the QT interval. The
3-day course of therapy can be completed orally
when the parasite density falls below 1% and the
patient can tolerate oral medication. A 7-day course
is needed if the disease is acquired in Thailand.
Potential indications for exchange transfusion
include parasite density >10% or severe complica-
tions such as altered mental status, non-volume
overload pulmonary edema, or renal disease. Intra-
venous quinidine is administered during the ex-
change, e
PREVENTION AND CHEMOPROPHYLAXIS
Prevention
Basic principles to improve the control of malaria
include 1) protection of the human from the Anoph-
eles mosquito, 2) reduction of the breeding and sur-
vival of the mosquito, 3) aggressive and early treat-
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TABLE 2. Prophylactic regimens safe for use in
pregnancy
Drug Dosage
Chloroquine
Proguanil
Pyrimethamine/
sulfadoxine
Mefloquine
300 mg base p.o. q week
200 mg p.o. daily (may be combined
with chloroquine)
75 mg/I,500 mg p.o. single dose, repeat
at beginning of the third trimester
250 mg salt p.o. q week
merit of the human disease, and 4) establishment
of surveillance and education programs,zs
Two newer devices for human protection in-
clude insecticide-impregnated bed nets and cur-
rains,z9 At the present time, studies of their effec-
tiveness are small and financial factors may limit
their usefulness.
Prophylaxis
Because prophylactic treatment can fail, it should
be emphasized that the optimal method for pre-
venting malarial infection in the non-immune
gravida is to refrain from travel to malaria-endemic
regions. When such travel is unavoidable, however,
there are several prophylactic regimens safe for use
in pregnancy (Table 2). The cost-effectiveness of
these regimens for women living in endemic re-
gions remains to be proven.
Mefloquine has been evaluated as prophylaxis
for chloroquine-resistant malaria.3 In a double-
blind, placebo-controlled study in Thailand, meflo-
quine gave >86% protection against P. falciparum
and complete protection against P. vivax. There
was no difference in either the mean birth weight
or the mean gestational age at delivery between the
two groups. Mcfloquine is not recommended for
use in the first trimester or in individuals with
known neurologic or psychiatric disorders. The
drug may provoke severe neuropsychiatric reac-
tions.3a
In Malawi, another area with chloroquine-
resistant malaria, prophylaxis was evaluated in
primi- and secundagravidas.3e Three regimens
were compared: chloroquine treatment followed by
chloroquine prophylaxis (CQ/CQ), sulfadoxine/
pyrimethamine treatment followed by chloroquine
prophylaxis (SP/CQ), and sulfadoxine/
pyrimethamine treatment and prophylaxis (SP/SP).
Combined treatment and prophylaxis with sulfa-
doxine/pyrimethamine resulted in a marked de-
crease in maternal parasitemia (32% for CQ/CQ
and 14% for SP/CQ vs 3% for SP/SP). Placental
parasitemia was also significantly reduced (32%,
25%, and 9%, respectively, for CQ/CQ, SP/CQ, and
SP/SP). Three percent of SP-treated infants devel-
oped scleral icterus; all cases resolved without com-
plications after phototherapy.
The effect of proguanil, either alone or in com-
bination with chloroquine, was evaluated by Mu-
tabingwa et al.3 Therapy was noted to reduce the
rate of low birth weight infants, however, due to
the small numbers of participants, the differences
were not significant.3 Placental parasitemia was
significantly reduced. In primigravidas, the preva-
lence of severe anemia was also reduced.
SUMMARY
Malaria is caused by four species of P/asmodium.
Infections in pregnant women are associated with
multiple complications including anemia, low birth
weight, and stillbirth. A high index of suspicion for
malaria in women emigrating from or traveling
through endemic areas is vital. Prompt diagnosis
and initiation of appropriate therapy may be life-
saving.
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